Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals Enthorin Therapeutics, LLC, a ...

Enthorin Therapeutics, LLC, a biotechnology company focused on circuit-modulating treatments for neurological and neurodevelopmental disorders, announced that its licensing partner for MRM-3379 ...

India has ordered Elon Musk’s X to make immediate technical and procedural changes to its AI chatbot Grok after users and lawmakers flagged the generation of “obscene” content, including AI-altered ...

Children with fragile X syndrome display widespread differences in brain morphology, including larger gray matter volume in subcortical regions and distinct brain-behavior correlations. Children with ...

NEW YORK, Dec 2 (Reuters) - The U.S. holiday shopping season kicked off to record online sales. But underlying signs of economic fragility signal a pullback in spending could be looming. Consumer ...

Mirum Pharmaceuticals MIRM announced that it has enrolled the first patient in the phase II BLOOM study evaluating its newly in-licensed PDE4D inhibitor, MRM-3379, for treating Fragile X syndrome (FXS ...

Proof-of-concept study underway for investigational oral therapy in Fragile X syndrome; top-line data from Phase 2 expected in 2027 FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that the first participant has been enrolled in the BLOOM Phase 2 ...

As the longest government shutdown in the history of the United States drags on, one sports pundit dared to shine a light on the suffering of NFL announcers who rely on private jets to traverse the ...

After its cannabidiol gel candidate failed a phase 3 trial in fragile X syndrome, Harmony Biosciences has now paused development of the asset in a different genetic disease. Harmony announced in ...

Mirum Pharmaceuticals ((MIRM)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...